ESALF News and Press, Eisai Co Ltd From 08/05/20

Eisai Co Ltd (ESALF) Q1 2021 Earnings Conference Call August 03, 2020 03:00 AM ET Company Participants Ryohei Yanagi - Chief Financial Officer Ivan Cheung - Senior VP & President of Neurology Business Group Terushige Iike - Senior VP & President of Oncology Business Gro...

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2021 Q1 earnings Read more ...

Eisai ( OTCPK:ESALF ) in collaboration with Alzheimer's Clinical Trials Consortium and Biogen (NASDAQ: BIIB ) has initiated a new global Phase 3 clinical study (AHEAD 3-45) with BAN2401, an anti-amyloid beta (Aβ) protofibril antibody. More news on: Eisai Co., Ltd., Biogen Inc....

TOKYO, July 6, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO? 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020. Eisai received marketing and manuf...

TOKYO, July 6, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020. Eisai received marketing and manufacturing approval for this for...

TOKYO, June 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide") for the indication of treatment of idiopathic Parkinson...

TOKYO, June 10, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel coronavirus infection in Africa, beginning with the activities described below. Through this su...

TOKYO, June 4, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the digital tool for self-assessment of brain performance (brain health) "NouKNOWTM" (pronounced "NOH-NOH", non- medical device), which Eisai has launched in Japan, is to be expanded in the fixed-rate membership beauty...

TOKYO, June 2, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or ...

Concerning the Dosage and Administration Related to the Indication of Hidradenitis Suppurativa TOKYO, May 29, 2020 - (JCN Newswire) - AbbVie GK and Eisai Co., Ltd. today announced an approval of partial changes in the marketing approval of HUMIRA (generic name: adalimumab [recombinant], here...